Brain–computer interfacing

Elite Education Group International Limited Announces Pricing of $6 Million Firm Commitment Initial Public Offering

Retrieved on: 
Thursday, March 25, 2021
Branches of biology, Brain–computer interfacing, Electrodiagnosis, Electroencephalography, Electrophysiology, Neurotechnology

MIDDLETOWN, Ohio, March 25, 2021 /PRNewswire/ -- Elite Education Group International Limited (Nasdaq: EEIQ) ("EEG"), a provider of comprehensive, one-stop education solutions for Chinese university students interested in study abroad programs in the US and other countries, today announced the pricing of its firm commitment initial public offering of 750,000units at an offering price of $8.00 per unit for total gross proceeds of $6.0 million.

Key Points: 
  • MIDDLETOWN, Ohio, March 25, 2021 /PRNewswire/ -- Elite Education Group International Limited (Nasdaq: EEIQ) ("EEG"), a provider of comprehensive, one-stop education solutions for Chinese university students interested in study abroad programs in the US and other countries, today announced the pricing of its firm commitment initial public offering of 750,000units at an offering price of $8.00 per unit for total gross proceeds of $6.0 million.
  • Each unit will immediately separate into one common share, one Series A warrant, and one Series B warrant.
  • The net proceeds to EEG from the sale of the securities are expected to be approximately $4.3 million, after deducting underwriting discounts and commissions and estimated offering expenses.
  • Elite Education Group International Limited, through its subsidiary Quest Holding International LLC, provides comprehensive, one-stop education solutions for Chinese students who are interested in study abroad programs in the US and other countries.

Brain Scientific Announces Collaboration with JelikaLite in New Clinical Trial

Retrieved on: 
Tuesday, March 16, 2021
Branches of biology, Neuroscience, Psychiatric diagnosis, Brain–computer interfacing, Electroencephalography, Electrophysiology, Neurotechnology, Autism, Neurology

In the clinical trial, brain treatments for children diagnosed with autism would be delivered through Cognilum, while Brain Scientifics NeuroEEG, a wireless EEG device, will monitor brain activity.

Key Points: 
  • In the clinical trial, brain treatments for children diagnosed with autism would be delivered through Cognilum, while Brain Scientifics NeuroEEG, a wireless EEG device, will monitor brain activity.
  • The clinical trial is designed to give researchers and clinicians an opportunity to potentially uncover new treatment options for reducing the symptoms children with autism experience.
  • Based in New York, JelikaLite was launched by a group of medical researchers and practitioners specializing in psychology, neurology and phototherapy.
  • Brain Scientifics next-generation neurology products continue to serve researchers, clinicians and others working in brain diagnostics and treatment.

Brain Scientific Featured in Syndicated Broadcast Covering Receipt of FDA Clearance for Next-Gen NeuroCap EEG Headset

Retrieved on: 
Friday, March 12, 2021
Branches of biology, Neuroscience, Electrophysiology, Neurophysiology, Electroencephalography, Brain–computer interfacing, Neurotechnology, 10–20 system

The audio press release covers Brain Scientifics receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for its next-generation NeuroCap device.

Key Points: 
  • The audio press release covers Brain Scientifics receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for its next-generation NeuroCap device.
  • NeuroCap is an advanced Electroencephalogram (EEG) electrode array used to obtain rapid EEGs in routine clinical and research settings where recording of STAT EEGs is desired.
  • To hear the audio production, visit: https://nnw.fm/um28X
    To read the original press release, visit: https://nnw.fm/TgVmq
    We are constantly working on new products for the EEG market.
  • NeuroCap is a disposable pre-gelled EEG headset with 22 electrodes and 19 active EEG channels located in accordance with the 10-20 system.

Cognito Therapeutics Announces Positive Phase 2 Results as First Digital Therapeutic to Improve Memory, Cognition, Functional Abilities and Reduce Brain Atrophy in Alzheimer’s Disease

Retrieved on: 
Tuesday, March 9, 2021
Science, Other Science, Research, Health, Mental health, Medical devices, Clinical trials, Other Health, Branches of biology, Neurophysiology, Neurotechnology, Electrophysiology, Neuropsychology, Brain–computer interfacing, Electroencephalography, Neuromodulation, Resting state fMRI

Gamma frequency neuromodulation is a novel digital therapeutic intervention for AD that utilizes EEG-calibrated auditory and visual stimuli to evoke patient-specific neural activity.

Key Points: 
  • Gamma frequency neuromodulation is a novel digital therapeutic intervention for AD that utilizes EEG-calibrated auditory and visual stimuli to evoke patient-specific neural activity.
  • Over the 6-month treatment period, subjects were regularly evaluated for cognitive, functional, and biomarker changes on multiple validated measures.
  • The study also evaluated changes in functional ability and brain volumetric changes in AD patients with mild to moderate cognitive impairment.
  • Brain volumetric changes were assessed by structural magnetic resonance imaging (MRI), taken at baseline and after six months of treatment.

Nanoscope's Optical Gene Therapies to be Featured at Optogenetics and Optical Manipulation 2021 Conference

Retrieved on: 
Friday, March 5, 2021
Branches of biology, Biology, Neuroscience, Brain–computer interfacing, Cybernetics, Neural engineering, Optics, Optogenetics, Retina, Neuromodulation, Opsin

BEDFORD, Texas, March 5, 2021 /PRNewswire/ -- Researchers of Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for treatment of retinal diseases, will make multiple scientific presentations featuring its groundbreaking research on optical gene delivery and opsin based neuromodulation therapy at the Optogenetics and Optical Manipulation 2021 virtual conference, March 6 11, 20201.

Key Points: 
  • BEDFORD, Texas, March 5, 2021 /PRNewswire/ -- Researchers of Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for treatment of retinal diseases, will make multiple scientific presentations featuring its groundbreaking research on optical gene delivery and opsin based neuromodulation therapy at the Optogenetics and Optical Manipulation 2021 virtual conference, March 6 11, 20201.
  • "Nanoscope is on the verge of significant breakthroughs in optical gene therapies for improving quality of life in people with retinal and neurological diseases," said Dr. Mohanty.
  • "We are developing both viralvector andnon-viral light delivery of genes to reprogram neurons and make them light-activatable, allowing therapeutic modulation."
  • Nanoscope also is developing an alternative, non-viral light-based gene delivery method that is designed to be more targeted with less immunogenicity.

New Research Highlights the Potential of Transforming Healthcare with Mobile EEG Brain Health Assessments

Retrieved on: 
Tuesday, February 23, 2021
Branches of biology, Neuroscience, Neurophysiology, Electrophysiology, Brain–computer interfacing, Electrodiagnosis, Neurotechnology, Electroencephalography, Draft:Wireless EEG, Brain–computer interface

The studies explore rapid EEG testing in varied environments, outside of clinical settings, laying the groundwork for the future of brain health.

Key Points: 
  • The studies explore rapid EEG testing in varied environments, outside of clinical settings, laying the groundwork for the future of brain health.
  • The study demonstrated that low-cost mEEG devices both conveniently and accurately measure EEG and human-event related brain potentials (ERPs) that can predict cognitive states like fatigue.
  • "Our work clearly demonstrates that mobile EEG systems can be used to quickly assess the brain state of people in any environment," says Krigolson.
  • "These results suggest a capacity to use mobile EEG technology for brain performance assessments in industry, healthcare, and personal use settings."

New Research Highlights the Potential of Transforming Healthcare with Mobile EEG Brain Health Assessments

Retrieved on: 
Tuesday, February 23, 2021
Branches of biology, Neuroscience, Neurophysiology, Electrophysiology, Brain–computer interfacing, Electrodiagnosis, Neurotechnology, Electroencephalography, Draft:Wireless EEG, Brain–computer interface

The studies explore rapid EEG testing in varied environments, outside of clinical settings, laying the groundwork for the future of brain health.

Key Points: 
  • The studies explore rapid EEG testing in varied environments, outside of clinical settings, laying the groundwork for the future of brain health.
  • The study demonstrated that low-cost mEEG devices both conveniently and accurately measure EEG and human-event related brain potentials (ERPs) that can predict cognitive states like fatigue.
  • "Our work clearly demonstrates that mobile EEG systems can be used to quickly assess the brain state of people in any environment," says Krigolson.
  • "These results suggest a capacity to use mobile EEG technology for brain performance assessments in industry, healthcare, and personal use settings."

Psychedelic Partnership Reached, Ehave Inc. and Brain Scientific Sign Memorandum of Understanding to Map Brain Response to Psychedelic Treatment, Collaborate in the Development of Neural Net Algorithms for the Psychedelic Mental Health Sector, E-Tattoo Te

Retrieved on: 
Wednesday, February 17, 2021
Branches of biology, Neurophysiology, Brain–computer interfacing, Neurotechnology, Emerging technologies, Electroencephalography, Electrophysiology, Brain, Psychology

This same functional lab can be used to study consumer behavior and psychology in markets Ehave operates for further commercialization of Ehaves data and technologies.

Key Points: 
  • This same functional lab can be used to study consumer behavior and psychology in markets Ehave operates for further commercialization of Ehaves data and technologies.
  • Brain Scientific is seeking to improve neurology by modernizing the brain diagnostic market with its cutting-edge technology.
  • As part of the MoU, Brain Scientific would provide its proprietary data signal acquisition devices, NeuroCap and NeuroEEG, for the Ehave platform.
  • All data from any transactions contemplated by the MoU will be jointly owned by both Ehave and Brain Scientific.

AGTC to Present at the 4th Annual Gene Therapy for Rare Disorders Digital Event, February 22-25, 2021

Retrieved on: 
Tuesday, February 16, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Brain–computer interfacing, Control theory, Cybernetics, Optics, Optogenetics, Therapy, Gene therapy

Dr. Knop will lead a pre-conference workshop, Unifying Process & Analytical Development to Establish Robust, Scalable Gene Therapy Manufacturing Processes on Monday, February 22 from 1:00 4:00 PM EST.

Key Points: 
  • Dr. Knop will lead a pre-conference workshop, Unifying Process & Analytical Development to Establish Robust, Scalable Gene Therapy Manufacturing Processes on Monday, February 22 from 1:00 4:00 PM EST.
  • The goal of the workshop is to share insights into the configuration of scalable gene therapy processes designed to pre-emptively overcome challenges to manufacturing for commercial markets.
  • AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs.
  • AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

Tobii, Valve, and OpenBCI Engaging in Research Collaboration to Make VR Gaming More Immersive

Retrieved on: 
Thursday, February 4, 2021
Branches of biology, Brain–computer interfacing, Articles, Science and technology, User interface techniques, Electroencephalography, Virtual reality, Open science, OpenBCI, Brain–computer interface, Valve Corporation, Valve Index

OpenBCI is an advanced technology company providing an open-source platform for applications related to brain computer interfacing (BCI).

Key Points: 
  • OpenBCI is an advanced technology company providing an open-source platform for applications related to brain computer interfacing (BCI).
  • Valve, one of the most influential companies in the gaming industry, has long been a pioneering force for the evolution of immersive gaming, entertainment content delivery, and the advancement of virtual reality hardware and experiences.
  • It is the first device that integrates EEG, EMG, EOG, EDA, PPG, and image based eye-tracking into a single headset.
  • The Galea Beta units will be built with elements from the Valve Index VR hardware.